Tesamorelin: GHRH Analog for Visceral Fat Research

FDA-approved growth hormone releasing hormone analog for metabolic research

Source: https://indexalabs.com/blog/tesamorelin-visceral-fat-reduction Abstract: Tesamorelin is an FDA-approved GHRH analog primarily researched for its effects on visceral adipose tissue. This guide covers its mechanism, clinical evidence, and research applications beyond its approved indication.

1. Overview

Tesamorelin is a synthetic GHRH analog with a trans-3-hexenoic acid modification that enhances stability and bioactivity. It is FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy, making it one of the few GH secretagogues with regulatory approval.

2. Mechanism of Action

2.1 GHRH Receptor Activation Tesamorelin binds to and activates GHRH receptors on pituitary somatotrophs, stimulating GH release.

2.2 Pulsatile GH Release Unlike exogenous GH, tesamorelin preserves the natural pulsatile pattern of GH secretion.

2.3 Lipolytic Effects Increased GH levels promote lipolysis, particularly in visceral adipose tissue.

3. Clinical Evidence

3.1 Visceral Fat Reduction Clinical trials demonstrated significant reductions in trunk fat and visceral adipose tissue.

3.2 Metabolic Parameters Improvements in triglycerides and adiponectin levels have been observed.

3.3 Cognitive Studies Emerging research suggests potential cognitive benefits in older adults.

4. Research Protocols

4.1 Available Sizes Tesamorelin is available in 10mg vials for research applications.

4.2 Administration Typically administered as a daily subcutaneous injection in clinical protocols.

4.3 Duration Considerations Clinical trials typically ran 26-52 weeks to assess metabolic effects.